Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 12358988
Proteolytically cleavable chimeric polypeptides and methods of use thereof
granted -
US 12357659
Production of megakaryocytes or platelets from monocytes
granted -
US 12358909
Capsazepine analogs for the treatment of cancer and other proliferative diseases
granted -
US 12357580
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
granted -
US 12357570
Chemoembolization agents
granted -
US 12359204
Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer
granted -
US 12357682
DNA plasmid-launched live-attanuated vaccines for plus-sense singel stranded RNA
granted -
US 12358971
Arena virus monoclonal antibodies and uses
granted -
US 12359219
Transgene cassettes designed to express a human MECP2 gene
granted -
US 12359220
Guided magnetic nanostructures for targeted and high-throughput intracellular delivery
granted -
US 12351609
Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
granted -
US 12351877
Systems and methods for determining a treatment course of action
granted -
US 12350399
Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use
granted -
US 12351649
Antibodies to oxidation-specific epitopes
granted -
US 12351560
Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
granted -
US 12350250
Aggrelytes for treating ocular conditions
granted -
US 12345709
CLAUDIN18 antibodies and methods of treating cancer
granted -
US 12343337
Compounds for increasing neural plasticity
granted -
US 12343397
Drug-resistant immune cells and methods of use thereof
granted -
US 12343424
Photochemically stable, non-leaching, bridged polysilsesquioxane based sunscreens
granted -
US 12343388
Clostridioides difficile TcdB variants, vaccines and methods of use
granted -
US 12336982
Compositions and methods of modulating short-chain dehydrogenase activity
granted -
US 12338459
DNA-chimeric antigen receptor T cells for immunotherapy
granted -
US 12337017
Microbiota transfer therapy for Pitt Hopkins Syndrome
granted -
US 12336976
Glutaminase inhibitor therapy
granted -
US 12331079
Oncolytic virus platform to treat cancers with myxoma virus
granted -
US 12329882
Aligned hydrogel tubes for tissue repair and regeneration
granted -
US 12332255
Methods for monitoring treatment of chronic liver disease
granted -
US 12329776
Treatment methods for ALS patients
granted -
US 12329827
Devices, compositions and related methods for accelerating and enhancing bone repair
granted -
US 12329780
Acute and chronic mitochondrial electron transport chain dysfunction treatments and graphenic materials for use thereof
granted -
US 12329457
Hyperspectral imaging for early detection of Alzheimer's disease
granted -
US 12329744
Methods of preparing extrudates
granted -
US 12329756
Regulation of eIF4E activity for migraine therapy
granted -
US 12331130
DDR1 antibodies and uses thereof
granted -
US 12329747
Use of lipophilic beta-lactam antibiotics and carboxylate esters for the treatment of bacterial infections within citrus and other plant species
granted -
US 12331307
Modified immunization vectors
granted -
US 12331078
Stabilizing mutants of prefusion SARS-CoV-2 (COVID-19) spike protein and improved yeast surface display engineering platform for the same
granted -
US 12332245
Cancer biomarkers and methods of use thereof
granted -
US 12329772
Methods and compositions for administration of iron
granted -
US 12331110
Monoclonal antibodies against endotrophin and the use thereof
granted -
US 12325691
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
granted -
US 12325710
Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders
granted -
US 12325715
Fluorous metal chelates compositions
granted -
US 12325705
Small molecules for the treatment of primary cancer and cancer metastasis
granted -
US 12324843
Compositions and methods for delivery of biomacromolecule agents
granted -
US 12325755
Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics
granted -
US 12325747
Human PD-L1 antibodies and methods of use therefor
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory